

5 years of CAR-T therapies




Chimeric antigen receptor T cell (CAR-T) therapy


Fighting cancer with a patient's own gene-modified white blood cells



6 FDA-approved since 2017¹




250+ in clinical development²



10K+ patients treated^{3,4}

In-patient treatment process⁵



Physician helps prevent and control possible side effects with medication and monitoring



2022: First cancer cure

In early 2022, a leukemia patient was declared cured via CAR-T therapy after 10 years cancer-free⁶



Oncologists recommend this novel treatment⁷ because of the promise it holds for better quality of life, longer life and even a cure.

Cost of therapy per patient \$375K to \$1M

Count on the experts at Cardinal Health Advanced Therapy Solutions

Cardinal Health has been working with CAR-Ts since **2017**

We provide treatment support for **90%** of active care sites⁸

Our team has processed **7K+** cell therapy orders⁸

We provide regulatory support for **12** advanced therapeutic areas⁸

Product development experience with **36** advanced therapies

Learn more at cardinalhealth.com/cellandgene



References: 1. FDA approval brings first gene therapy to the United States [news release]. FDA; August 30, 2017. <https://www.fda.gov/news-events/press-announcements/fda-approval-brings-first-gene-therapy-united-states>. Accessed July 7, 2022. 2. Comprehensive analysis of 250+ key companies developing 250+ novel CAR-T therapies [news release]. Los Angeles, CA: DelveInsight; April 20, 2021. <https://www.globenewswire.com/news-release/2021/04/21/2213788/0/en/Comprehensive-Analysis-of-250-Key-Companies-Developing-250-Novel-CAR-T-Therapies-DelveInsight.html>. Accessed July 7, 2022. 3. FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma [news release]. East Hanover, NJ: BioSpace; May 27, 2022. <https://www.biospace.com/article/releases/fda-approves-novartis-kymriah-car-t-cell-therapy-for-adult-patients-with-relapsed-or-refractory-follicular-lymphoma>. Accessed July 7, 2022. 4. Support and resources. YESCARTA® (axicabtagene ciloleucel). Yescarta HCP Web site. <https://www.yescartahcp.com/large-b-cell-lymphoma/support-and-resources>. Accessed July 7, 2022. 5. Frequently asked questions about CAR-T cell therapy. Dana-Farber Cancer Institute. <https://www.dana-farber.org/cellular-therapies-program/car-t-cell-therapy/faq-about-car-t-cell-therapy>. Accessed July 7, 2022. 6. Chen A. Researchers label early CAR-T therapy patient 'cured' after living a decade without cancer. <https://www.statnews.com/2022/02/02/cart-cancer-therapy-leukemia-treatment>. Published February 2, 2022. Accessed July 7, 2022. 7. Amorosi D. CAR-T provides value despite high price tag, oncologists say. <https://www.healio.com/news/hematology-oncology/2021/12/13/cart-provides-value-despite-high-price-tag-oncologists-say>. Published December 13, 2021. Accessed July 7, 2022. 8. Search for a FACT accredited organization. Foundation for the Accreditation of Cellular Therapy. https://accredited.factglobal.org/?_sif_category=cellular-therapy. Accessed July 7, 2022.